Topic: Thomson Reuters Corporation
STOCKHOLM (Reuters) - Sanofi-Aventis's recently launched heart rhythm drug Multaq should be considered as a treatment option for patients with atrial fibrillation, a common arrhythmia, according to new medical guidelines.Multaq, or dronedarone, was designed as a improvement on the older drug amiodarone. ...
CHICAGO (Modern Healthcare) - Reducing patients' risk of unnecessary readmission to the hospital after discharge is a lot like untangling the spaghetti of wires tucked behind most people's television/sound systems. At least that has been the experience at Rush University Medical Center ...
CHICAGO (Modern Healthcare) - Reducing patients' risk of unnecessary readmission to the hospital after discharge is a lot like untangling the spaghetti of wires tucked behind most people's television/sound systems. At least that has been the experience at Rush University Medical Center ...
NEW YORK (Reuters Health) - About 3 million Americans suffer from the most common type of abnormal heart rhythm, atrial fibrillation, and that number is likely to double by 2035, new research shows.Atrial fibrillation occurs when the two upper chambers of the ...
